Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules-Reference-Cited by-同舟云学术

Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules

Published:2015-07 Issue:1 Volume:28 Page:82-96
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Yu Yu,Gaillard Stephanie,Phillip Jude M.,Huang Tai-Chung,Pinto Sneha M.,Tessarollo Nayara G.,Zhang Zhen,Pandey Akhilesh,Wirtz Denis,Ayhan Ayse,Davidson Ben,Wang Tian-Li,Shih Ie-Ming

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference52 articles.

1. Targeted disruption of the JAK2/STAT3 pathway in combination with systemic administration of paclitaxel inhibits the priming of ovarian cancer stem cells leading to a reduced tumor burden;Abubaker;Front Oncol,2014

2. Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel;Ahmed;Cancer Res.,2011

3. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation;Braselmann;J. Pharmacol. Exp. Ther.,2006

4. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia;Buchner;Cancer Res.,2009

5. Phosphorylation of MAP4 affects microtubule properties and cell cycle progression;Chang;J. Cell Sci.,2001

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors;Cancer Research Communications;2024-09-01

2. Development of a high-throughput kinase activity platform using nanoLC-MS/MS with DIA approach for studying the anti-cancer mechanism of Taxol in ovarian cancer;Analytica Chimica Acta;2024-08

3. Targeting NOTCH2-JAG1 juxtacrine signaling reverses macrophage-mediated tumor resistance to taxol;2024-07-10

4. Cancer nuclear envelope rupture and repair in taxane resistance;Medical Review;2024-06-05

5. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors;ESMO Open;2024-06